Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
Strong U.S. demand and new product launches drive first-half sales in Human Pharma Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches Positive Phase III data for…
Read the full articleYou might also wanna read
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
Strong U.S. demand and new product launches drive first-half sales in Human PharmaNet sales reach EUR 15.8 billion, led by JARDIANCE® and su
Boehringer Ingelheim steigert Umsatz im ersten Halbjahr 2026 dank der anhaltend starken Nachfrage nach JARDIANCE® sowie neuer Produkteinführungen in den USA
Ingelheim (ots) - - Starke Nachfrage in den USA sowie neue Produkteinführungen treiben das Wachstum in der Humanpharma - Konzernumsatz errei
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will repo
After two years, pharma volumes pick up pace
Domestic pharmaceutical retail growth shows strong signs of demand-led expansion. Volume growth in June exceeded three percent, a significan
OTS: Boehringer Ingelheim / Boehringer Ingelheim steigert Umsatz im ersten .
Boehringer Ingelheim steigert Umsatz im ersten Halbjahr 2026 dank der anhaltend starken Nachfrage nach JARDIANCE® sowie neuer Produkteinführ
J&J MedTech growth slows again in Q2 as Abiomed weighs on results
Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiome
Comments
Sign in to join the conversation.
No comments yet. Be the first.